HRP20210052T1 - Modulatori adenozinskog receptora a3 - Google Patents

Modulatori adenozinskog receptora a3 Download PDF

Info

Publication number
HRP20210052T1
HRP20210052T1 HRP20210052TT HRP20210052T HRP20210052T1 HR P20210052 T1 HRP20210052 T1 HR P20210052T1 HR P20210052T T HRP20210052T T HR P20210052TT HR P20210052 T HRP20210052 T HR P20210052T HR P20210052 T1 HRP20210052 T1 HR P20210052T1
Authority
HR
Croatia
Prior art keywords
pyridin
cyano
piperidine
carboxylic acid
thiazol
Prior art date
Application number
HRP20210052TT
Other languages
English (en)
Inventor
Julio Castro Palomino Laria
Juan CAMACHO GÓMEZ
Abdelaziz EL MAATOUGUI
Original Assignee
Palobiofarma, S.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palobiofarma, S.L. filed Critical Palobiofarma, S.L.
Publication of HRP20210052T1 publication Critical patent/HRP20210052T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (11)

1. Spoj formule (I): [image] , naznačen time što: – R1 predstavlja fenilnu skupinu ili petero- ili šesteročlanu heteroarilnu skupina s jednim, dva ili tri heteroatoma, koje se bira između O, S i N, koja može biti supstituiran s 1, 2 ili 3 supstituenta, koje se bira iz skupine koju čine atom halogena, nerazgranati ili razgranati C1-C6 halogenalkil, nerazgranati ili razgranati C1-C6 alkil, nerazgranati ili razgranati C1-C6 alkoksi i skupina cijano, i njegove farmaceutski prihvatljive soli.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time što R1 predstavlja petero- ili šesteročlanu heteroarilnu skupinu, koja može biti supstituirana s 1, 2 ili 3 supstituenta, koje se bira iz skupine koju čine atom halogena, nerazgranati ili razgranati C1-C6 halogenalkil, nerazgranati ili razgranati C1-C6 alkil, nerazgranati ili razgranati C1-C6 alkoksi i skupina cijano.
3. Spoj u skladu s patentnim zahtjevom 2, naznačen time što R1 predstavlja skupinu koju se bira između tienil, furil, piridil i tiazolil koji može biti supstituiran s 1, 2 ili 3 supstituenta, koje se bira iz skupine koju čine atom halogena, nerazgranati ili razgranati C1-C6 alkil, nerazgranati ili razgranati C1-C6 alkoksi i skupina cijano.
4. Spoj u skladu s patentnim zahtjevom 3, naznačen time što R1 predstavlja tienilnu skupinu, koja može biti supstituirana s 1, 2 ili 3 supstituenta, koje se bira iz skupine koju čine atom halogena i nerazgranati ili razgranati C1-C6 alkoksi.
5. Spoj u skladu s patentnim zahtjevom 3, naznačen time što R1 predstavlja fenilnu skupinu, koja može biti supstituirana s 1 ili 2 supstituenta, koje se bira iz skupine koju čine atom halogena i nerazgranati ili razgranati C1-C6 alkoksi.
6. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je jedan od: 1-(5-(5-cijano-4-feniltiazol-2-ilkarbamoil)piridin-2-il)piperidin-4-karboksilne kiseline; 1-(5-((5-cijano-4-(2-metoksifenil)tiazol-2-il)karbamoil)piridin-2-il)piperidin-4-karboksilne kiseline; 1-(5-((5-cijano-4-(3-metoksifenil)tiazol-2-il)karbamoil)piridin-2-il)piperidin-4-karboksilne kiseline; 1-(5-(5-cijano-4-(4-metoksifenil)tiazol-2-ilkarbamoil)piridin-2-il)piperidin-4-karboksilne kiseline; 1-(5-((5-cijano-4-(2-fluorfenil)tiazol-2-il)karbamoil)piridin-2-il)piperidin-4-karboksilne kiseline; 1-(5-((5-cijano-4-(3-fluorfenil)tiazol-2-il)karbamoil)piridin-2-il)piperidin-4-karboksilne kiseline; 1-(5-((5-cijano-4-(4-fluorfenil)tiazol-2-il)karbamoil)piridin-2-il)piperidin-4-karboksilne kiseline; 1-(5-((4-(2-klorfenil)-5-cijanotiazol-2-il)karbamoil)piridin-2-il)piperidin-4-karboksilne kiseline; 1-(5-((5-cijano-4-(piridin-2-il)tiazol-2-il)karbamoil)piridin-2-il)piperidin-4-karboksilne kiseline; 1-(5-((5-cijano-4-(piridin-3-il)tiazol-2-il)karbamoil)piridin-2-il)piperidin-4-karboksilne kiseline; 1-(5-(5-cijano-4-(piridin-4-il)tiazol-2-ilkarbamoil)piridin-2-il)piperidin-4-karboksilne kiseline; 1-(5-(5-cijano-4-(6-metoksipiridin-3-il)tiazol-2-ilkarbamoil)piridin-2-il)piperidin-4-karboksilne kiseline; 1-(5-(5-cijano-4-(furan-2-il)tiazol-2-ilkarbamoil)piridin-2-il)piperidin-4-karboksilne kiseline; 1-(5-(5-cijano-4-(tiofen-2-il)tiazol-2-ilkarbamoil)piridin-2-il)piperidin-4-karboksilne kiseline; 1-(5-(5-cijano-4-(tiofen-3-il)tiazol-2-ilkarbamoil)piridin-2-il)piperidin-4-karboksilne kiseline; 1-(5-((4-(4-klortiofen-2-il)-5-cijanotiazol-2-il)karbamoil)piridin-2-il)piperidin-4-karboksilne kiseline; 1-(5-(5-cijano-4-(tiazol-2-il)tiazol-2-ilkarbamoil)piridin-2-il)piperidin-4-karboksilne kiseline.
7. Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 6, ili njegovu farmaceutski prihvatljivu sol, kao i farmaceutski prihvatljivi razrjeđivač ili nosač.
8. Spoj u skladu s patentnih zahtjeva 1 do 6, naznačen time što je namijenjen upotrebi u liječenju bolesti ili patološkog stanja kojeg se može ublažiti moduliranjem adenozinskog receptora A3.
9. Spoj u skladu s patentnim zahtjevom 8, naznačen time što je namijenjen upotrebi u liječenju bolesti ili patološkog stanja kojeg se može ublažiti moduliranjem adenozinskog receptora A3, kojeg se bira iz skupine koju čine ateroskleroza, astma, rak prostate, akutno zatajenje bubrega, reumatoidni artritis, psorijaza, imunosna trombocitopenija, Crohnova bolest, kolitis, sindrom iritabilnih crijeva, glaukom, sindrom suhog oka, uveitis i neuropatska bol.
10. Kombinacija, naznačena time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 6 i terapijsko sredstvo kojeg se upotrebljava u liječenju bolesti koje se bira iz skupine koju čine ateroskleroza, astma, rak prostate, akutno zatajenje bubrega, reumatoidni artritis, psorijaza, imunosna trombocitopenija, Crohnova bolest, kolitis, sindrom iritabilnih crijeva, glaukom, sindrom suhog oka, uveitis i neuropatska bol.
11. Kombinacija, naznačena time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 6 i terapijsko sredstvo kojeg se bira iz skupine koju čine atorvastatin, rosuvastatin, simvastatin, montelukast, bikalutamid, flutamid, tofacitinib, hidroklorotiazid i lubiproston.
HRP20210052TT 2017-01-20 2021-01-12 Modulatori adenozinskog receptora a3 HRP20210052T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES201730065A ES2676535B1 (es) 2017-01-20 2017-01-20 Moduladores de los receptores a3 de adenosina
EP18716648.3A EP3581572B8 (en) 2017-01-20 2018-01-19 Adenosine a3 receptor modulators
PCT/ES2018/070039 WO2018134464A1 (es) 2017-01-20 2018-01-19 Moduladores de los receptores a3 de adenosina

Publications (1)

Publication Number Publication Date
HRP20210052T1 true HRP20210052T1 (hr) 2021-03-05

Family

ID=61913194

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20210052TT HRP20210052T1 (hr) 2017-01-20 2021-01-12 Modulatori adenozinskog receptora a3

Country Status (22)

Country Link
US (1) US10744125B2 (hr)
EP (1) EP3581572B8 (hr)
JP (1) JP7032410B2 (hr)
KR (1) KR102483091B1 (hr)
CN (1) CN110198939B (hr)
AU (1) AU2018209271B2 (hr)
BR (1) BR112019012464A2 (hr)
CA (1) CA3048604A1 (hr)
CY (1) CY1123843T1 (hr)
DK (1) DK3581572T3 (hr)
EA (1) EA038011B1 (hr)
ES (2) ES2676535B1 (hr)
HR (1) HRP20210052T1 (hr)
HU (1) HUE052437T2 (hr)
LT (1) LT3581572T (hr)
MX (1) MX2019008554A (hr)
PL (1) PL3581572T3 (hr)
PT (1) PT3581572T (hr)
RS (1) RS61424B1 (hr)
SI (1) SI3581572T1 (hr)
WO (1) WO2018134464A1 (hr)
ZA (1) ZA201904333B (hr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7233087B2 (ja) * 2019-03-18 2023-03-06 公立大学法人横浜市立大学 抗動脈硬化剤
EP3957308A1 (en) * 2020-08-21 2022-02-23 Palobiofarma, S.L. (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09291089A (ja) * 1996-04-26 1997-11-11 Yamanouchi Pharmaceut Co Ltd 新規な５−チアゾリルウラシル誘導体又はその塩
ATE257703T1 (de) 1997-10-27 2004-01-15 Takeda Chemical Industries Ltd 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes
AU4506399A (en) * 1998-06-05 1999-12-30 Novartis Ag Aryl pyridinyl thiazoles
JP2003522729A (ja) 1998-07-16 2003-07-29 ザ トラスティーズ オヴ ザ ユニヴァーシティー オヴ ペンシルバニア 眼内圧の低下方法
US6448253B1 (en) 1998-09-16 2002-09-10 King Pharmaceuticals Research And Development, Inc. Adenosine A3 receptor modulators
JP3333774B2 (ja) 1999-04-23 2002-10-15 武田薬品工業株式会社 ５−ピリジル−１，３−アゾール化合物、その製造法及び用途
PL351148A1 (en) * 1999-04-23 2003-03-24 Takeda Chemical Industries Ltd 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof
JP2003525291A (ja) 2000-03-01 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ２，４−二置換チアゾリル誘導体
US6358964B1 (en) * 2000-07-26 2002-03-19 King Pharmaceuticals Research And Development, Inc. Adenosine, A3 receptor modulators
GB0028383D0 (en) * 2000-11-21 2001-01-03 Novartis Ag Organic compounds
WO2003008884A1 (en) 2001-07-16 2003-01-30 Maytag Corporation Refrigerator shelves with rolled hook for cantilever fastening
MXPA06001254A (es) 2003-07-31 2006-05-17 Sanofi Aventis Derivados de aminoquinolina y su uso como ligantes de adenosina a3.
EP3002283B1 (en) 2003-12-26 2017-06-14 Kyowa Hakko Kirin Co., Ltd. Thiazole derivatives
ATE502640T1 (de) 2006-01-26 2011-04-15 Us Gov Health & Human Serv Allosterische a3-adenosin-rezeptormodulatoren
WO2007116106A1 (es) * 2006-04-12 2007-10-18 Palobiofarma, S.L. Nuevos compuestos como antagonistas de los receptores a1 de adenosina
US20100062994A1 (en) 2006-07-14 2010-03-11 Santaris Pharma A/S Adenosine Receptor Antagonists
AU2007307157A1 (en) 2006-10-06 2008-04-17 The Trustees Of The University Of Pennsylvania Effective delivery of cross-species A3 adenosine-receptor antagonists to reduce intraocular pressure
WO2009010871A2 (en) * 2007-07-13 2009-01-22 Addex Pharma S.A. Pyrazole derivatives as antagonists of adenosine a3 receptor
ES2331220B1 (es) * 2007-10-02 2010-09-23 Palobiofarma, S.L. Nuevos compuestos como antagonistas de los receptores a1 de adenosina.
US20090099212A1 (en) 2007-10-16 2009-04-16 Jeff Zablocki A3 adenosine receptor antagonists
WO2010009190A1 (en) 2008-07-16 2010-01-21 King Pharmaceuticals Research And Development, Inc. Methods of treating atherosclerosis
US8796291B2 (en) 2008-08-01 2014-08-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor antagonists and partial agonists
US9199102B2 (en) 2009-07-21 2015-12-01 Oradin Pharmaceutical Ltd. A3 adenosine receptor ligands for modulation of pigmentation
WO2012030918A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Adenosine a3 receptor modulating compounds and methods of use thereof
ES2896354T3 (es) * 2012-12-21 2022-02-24 Astellas Inst For Regenerative Medicine Métodos para la producción de plaquetas a partir de células madre pluripotentes
ES2578363B1 (es) * 2015-01-22 2017-01-31 Palobiofarma, S.L. Moduladores de los receptores A3 de adenosina

Also Published As

Publication number Publication date
ES2676535A1 (es) 2018-07-20
EA201991728A1 (ru) 2019-12-30
RS61424B1 (sr) 2021-03-31
DK3581572T3 (da) 2021-01-18
KR20190105226A (ko) 2019-09-16
PL3581572T3 (pl) 2021-05-31
CN110198939A (zh) 2019-09-03
LT3581572T (lt) 2021-02-25
ES2676535B1 (es) 2019-04-29
ZA201904333B (en) 2020-12-23
EP3581572B1 (en) 2020-11-25
JP7032410B2 (ja) 2022-03-08
US20190374530A1 (en) 2019-12-12
PT3581572T (pt) 2021-02-09
MX2019008554A (es) 2019-09-19
EP3581572A1 (en) 2019-12-18
KR102483091B1 (ko) 2023-01-02
CY1123843T1 (el) 2022-05-27
AU2018209271B2 (en) 2021-03-11
BR112019012464A2 (pt) 2020-04-14
WO2018134464A1 (es) 2018-07-26
HUE052437T2 (hu) 2021-04-28
JP2020505349A (ja) 2020-02-20
CN110198939B (zh) 2023-03-28
EA038011B1 (ru) 2021-06-22
EP3581572B8 (en) 2021-03-24
US10744125B2 (en) 2020-08-18
CA3048604A1 (en) 2018-07-26
SI3581572T1 (sl) 2021-04-30
AU2018209271A1 (en) 2019-07-04
ES2847385T3 (es) 2021-08-03

Similar Documents

Publication Publication Date Title
HRP20210052T1 (hr) Modulatori adenozinskog receptora a3
HRP20181076T1 (hr) Pirazolski derivati kao modulatori kalcijevih kanala aktiviranih oslobađanjem kalcija
AU2018236691B2 (en) N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
HRP20210769T1 (hr) Supstituirani 3-azabiciklo[3.1.0]heksani kao inhibitori ketoheksokinaze
JP2016196492A5 (hr)
HRP20140593T1 (hr) Derivati 1,3-disupstituiranih imidazolidin-2-ona kao cyp 17-inhibitori
HRP20201444T1 (hr) Farmaceutski spojevi
HRP20190815T1 (hr) Piridonski derivati korišteni kao inhibitori kinaze reorganizirane tijekom transfekcije (ret)
JP2013501720A5 (hr)
JP2012526803A5 (hr)
RU2011147185A (ru) Азетидинилдиамиды в качестве ингибиторов моноацилглицерин-липазы
HRP20191779T1 (hr) Tiazolski modulatori adenozinskih receptora a3
JP2016523911A5 (hr)
HRP20180272T1 (hr) Benzamidi
HRP20201400T1 (hr) Spojevi 6-aril-4-(morfolin-4-il)-1h-piridin-2-ona korisni za liječenje karcinoma i dijabetesa
JP2011517458A5 (hr)
JP2014508128A5 (hr)
JP2008526840A5 (hr)
HRP20230789T1 (hr) Derivati benzhidroksamske kiseline kao selektivni inhibitori hdac6
HRP20160608T1 (hr) Novi disupstituirani spojevi 3,4-diamino-3-ciklobuten-1,2-diona, namijenjeni upotrebi u liječenju bolesti posredovanih kemokinima
JP2005514432A5 (hr)
RU2017118165A (ru) Ингибиторы энхансера гомолога 2 zestes
JP2010540462A5 (hr)
JP2009528284A5 (hr)
JP2013517279A5 (hr)